Establishment Labs Announces First Mia Femtech™ Partners in Europe and Second Partner Chain in Japan
23 March 2023 - 11:00PM
Business Wire
Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
today announced it has entered into agreements with four partners
in Europe and a second partner chain in Japan for Mia Femtech™
(“Mia®”).
“Our global rollout of Mia Femtech continues, and we are pleased
to announce our first European partners in Sweden, Switzerland, and
Spain, as well as an additional chain in Japan,” said Juan José
Chacón-Quirós, Founder and Chief Executive Officer. “We expect to
partner with many more centers with a focus on creating premium
experiences with broad appeal. Mia is opening breast aesthetics to
a new group of consumers and the strong interest in partnering with
us demonstrates the potential of Mia to dramatically expand our
markets. We look forward to many more announcements on Mia over the
coming weeks and months.”
In Stockholm, Sweden, Establishment Labs is partnering with
Nordiska Kliniken, one of Scandinavia’s leading clinics in plastic
surgery and aesthetic treatments. In Switzerland, the Company is
working with Leman Aesthetic Clinic in Geneva and Clinic Utoquai in
Zurich, which are both internationally recognized and
well-established leaders in aesthetics. In Barcelona, Spain,
Clínica Planas is well-known as a provider of premium services and
outcomes in plastic surgery. Joe Clinic is a high-end medical
aesthetics chain in Japan that will begin initially by offering Mia
at its Tokyo and Osaka locations.
“Mia Femtech will define a new premium aesthetic category with
great potential for expanding the market,” said Javier Planas, CEO
of Clínica Planas. “Clínica Planas has been a pioneer in aesthetics
since 1971, and we are excited to once again be at the forefront of
innovation and excellence.”
“As leaders in plastic surgery, we are proud to introduce Mia
Femtech as the coming evolution in breast aesthetics. Building
Nordiska Kliniken has always been about innovating and this is the
next natural step in our journey of being market leaders,” said Sam
Besara, CEO of Nordiska Kliniken.
Mia Femtech is Establishment Labs’ breakthrough minimally
invasive breast aesthetics experience. The patented technologies
used with Mia can shape the breast up 1 to 2 cups in a 15-minute
procedure without the need for general anesthesia.
Mia Femtech is not yet commercially available in the European
Union and the United States.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The over 2.5 million Motiva®
devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is the only
regulatory-approved expander in the world with an integrated port
that is MRI conditional and is used to improve outcomes in breast
reconstruction following breast cancer. Mia Femtech™, Establishment
Lab’s unique minimally invasive experience for breast harmony, is
the Company’s most recent breakthrough innovation. These solutions
are supported by over 200 patent applications in 25 separate patent
families worldwide and over 50 scientific studies and publications
in peer reviewed journals. Establishment Labs manufactures at two
facilities in Costa Rica compliant with all applicable regulatory
standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP
program. In 2018, the Company received an investigational device
exemption (IDE) from the FDA for Motiva Implants® and began a
clinical trial to support regulatory approval in the United States.
Please visit our website for additional information at
www.establishmentlabs.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). You can find many (but not all) of
these statements by looking for words such as “approximates,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “intends to,” “would,” “will,” “may” or other similar
expressions in this press release. Any statements that refer to
projections of our future financial or operating performance,
anticipated trends in our business, our goals, strategies, focus
and plans, including related product development and
commercialization and regulatory approvals, and other
characterizations of future events or circumstances, including
statements expressing general optimism about future operating
results, related to the company’s performance are forward-looking
statements. We claim the protection of the safe harbor contained in
the Private Securities Litigation Reform Act of 1995. We caution
investors that any forward-looking statements presented in this
report, or that we may make orally or in writing from time to time,
are expressions of our beliefs and expectations based on currently
available information at the time such statements are made. Such
statements are based on assumptions, and the actual outcome will be
affected by known and unknown risks, trends, uncertainties, and
factors that are beyond our control. Although we believe that our
assumptions are reasonable, we cannot guarantee future performance,
and some will inevitably prove to be incorrect. As a result, our
actual future results and the timing of events may differ from our
expectations, and those differences may be material. Factors, among
others, that could cause actual results and events to differ
materially from those described in any forward-looking statements
include risks and uncertainties relating to: our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product offerings;
the rate of adoption of our products by healthcare providers or
other customers; the success of our marketing initiatives; the safe
and effective use of our products; our ability to protect our
intellectual property; our future expansion plans and capital
allocation; our ability to expand upon and/or secure sources of
credit or capital; our ability to develop and maintain
relationships with qualified suppliers to avoid a significant
interruption in our supply chains; our ability to attract and
retain key personnel; our ability to scale our operations to meet
market demands; the effect on our business of existing and new
regulatory requirements; and other economic and competitive
factors. These and other factors that could cause or contribute to
actual results differing materially from our expectations include,
among others, those risks and uncertainties discussed in the
company’s quarterly report and annual reports, and other filings
made by the company with the Securities and Exchange Commission.
The risks included in those documents are not exhaustive, and
additional factors could adversely affect our business and
financial performance. We operate in a very competitive and rapidly
changing environment. New risk factors emerge from time to time,
and it is not possible for us to predict all such risk factors, nor
can we assess the impact of all such risk factors on our business
or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in
any forward-looking statements. We are not undertaking any
obligation to update any forward-looking statements. Accordingly,
investors should use caution in relying on past forward-looking
statements, which are based on known results and trends at the time
they are made, to anticipate future results or trends.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230323005283/en/
Investor/Media Contact: Raj Denhoy 415-828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Apr 2023 to Apr 2024